STRADA Gene Polyhydramnios Megalencephaly and Symptomatic Epilepsy Genetic Test
At DNA Labs UAE, we offer the STRADA Gene Polyhydramnios Megalencephaly and Symptomatic Epilepsy Genetic Test. This test is designed to diagnose a rare genetic disorder known as polyhydramnios, megalencephaly, and symptomatic epilepsy (PMSE).
Test Details
The STRADA gene is associated with PMSE, which is characterized by excessive amniotic fluid during pregnancy (polyhydramnios), an abnormally large brain (megalencephaly), and the presence of seizures (symptomatic epilepsy). Our NGS (Next-Generation Sequencing) technology allows us to analyze multiple genes simultaneously to identify any variations or mutations in the STRADA gene that may be responsible for the development of PMSE.
Test Components and Price
The cost of the STRADA Gene Polyhydramnios Megalencephaly and Symptomatic Epilepsy Genetic Test is AED 4400.0. The sample condition required for the test is either blood, extracted DNA, or one drop of blood on an FTA card.
Report Delivery
The report for the test will be delivered within 3 to 4 weeks.
Test Type and Department
The test falls under the category of dysmorphology and is conducted by our expert team in the Genetics department.
Pre Test Information
Prior to the test, it is important to provide the clinical history of the patient who is undergoing the STRADA Gene Polyhydramnios, Megalencephaly, and Symptomatic Epilepsy NGS Genetic DNA Test. Additionally, a genetic counseling session will be conducted to draw a pedigree chart of family members affected by PMSE.
Doctor and Test Department
The test is conducted by our experienced pediatricians in the Genetics department.
Benefits of the Test
The STRADA Gene Polyhydramnios Megalencephaly and Symptomatic Epilepsy Genetic Test can help confirm a diagnosis of PMSE and provide important information about the underlying cause of the disorder. This information is valuable for guiding treatment decisions and providing genetic counseling to affected individuals and their families.
| Test Name | STRADA Gene Polyhydramnios megalencephaly and symptomatic epilepsy Genetic Test |
|---|---|
| Components | |
| Price | 4400.0 AED |
| Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Dysmorphology |
| Doctor | Pediatrics |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for STRADA Gene Polyhydramnios, megalencephaly, and symptomatic epilepsy NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with STRADA Gene Polyhydramnios, megalencephaly, and symptomatic epilepsy NGS Genetic DNA Test gene STRADA |
| Test Details |
The STRADA gene is associated with a rare genetic disorder known as polyhydramnios, megalencephaly, and symptomatic epilepsy (PMSE). This disorder is characterized by excessive amniotic fluid during pregnancy (polyhydramnios), an abnormally large brain (megalencephaly), and the presence of seizures (symptomatic epilepsy). NGS (Next-Generation Sequencing) genetic testing is a type of genetic testing that analyzes multiple genes simultaneously to identify any variations or mutations that may be associated with a particular disorder. In the case of PMSE, NGS genetic testing can be used to identify any variations or mutations in the STRADA gene that may be responsible for the development of the disorder. By identifying these genetic variations or mutations, NGS genetic testing can help in confirming a diagnosis of PMSE and provide important information for understanding the underlying cause of the disorder. This information can be valuable for guiding treatment decisions and providing genetic counseling to affected individuals and their families. |
